A Phase 3 interventional study of ITI-007 (Lumateperone) and Placebo in Bipolar Depression, sponsored by Intra-Cellular Therapies, Inc.. Completed at 55 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-03.
Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Bipolar Disorder by Johnson & Johnson — 2 open to participants now, 2 under way, 2 of them phase 3. Bipolar Disorder · Johnson & Johnson.
Among the 39 studies in Bipolar Disorder by Johnson & Johnson, this one is the 4th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2015, is one of 28 in phase 3, and was the 30th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.
Browse Bipolar Disorder studies →2 of the 39 studies in Bipolar Disorder by Johnson & Johnson are open now, in 4 countries. Recruiting first, the newest first:
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, India and 1 more country
Ages 10–17
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, Serbia
Ages 5–17
By country, each count listing its studies:
Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 554 is above the median of 64 across 1,279 interventional studies indexed under Bipolar Disorder.
Median enrollment 300 across the 36 interventional studies, 1,066 across the 3 observational. Of the 37 that completed or were terminated, 9 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Intra-Cellular Therapies, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 39 studies in Bipolar Disorder by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the efficacy and safety of ITI-007 (Lumateperone) in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode. The study will be conducted in two parts, Part A and Part B. Part A is a randomized, double-blind, placebo-controlled study. In Part B, patients who safely complete participation in part A may be enrolled in an open-label extension.
Major Inclusion Criteria:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
Drug: ITI-007 (Lumateperone)
60 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
Drug: ITI-007 (Lumateperone)
Placebo administered orally as visually-matched capsules once daily for 6 weeks
Drug: Placebo
Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.
Time frame: 6 weeks
Time to First Sustained Response in Reduction of MADRS Total Score
Time frame: 6 weeks
Change From Baseline to Day 175 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
The MADRS total score from baseline to Day 175 for patients that rolled over into the extension portion of the study (Part B)
Time frame: Day 175
Adverse Events
Incidence of Treatment-Emergent Adverse Events from baseline to Day 175 for patients that rolled over into the extension portion of the study (Part B)
Time frame: Day 175
| Milestone | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo |
|---|---|---|---|
| Started | 183 | 185 | 186 |
| Number of patients randomized and took at least 1 dose of study drug | 180 | 184 | 185 |
| Completed | 126 | 113 | 138 |
| Not completed | 57 | 72 | 48 |
| Withdrew: Adverse event | 13 | 15 | 4 |
| Withdrew: Lack of efficacy | 2 | 4 | 2 |
| Withdrew: Protocol violation | 13 | 10 | 14 |
| Withdrew: Physician decision | 2 | 3 | 4 |
| Withdrew: Withdrawal by subject | 15 | 11 | 14 |
| Withdrew: Lost to follow-up | 12 | 28 | 10 |
| Withdrew: Non-compliant with site request | 0 | 1 | 0 |
| Milestone | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo |
|---|---|---|---|
| Started | 0 | 127 | 0 |
| Completed | 0 | 74 | 0 |
| Not completed | 0 | 53 | 0 |
| Withdrew: Adverse event | 0 | 12 | 0 |
| Withdrew: Lack of efficacy | 0 | 4 | 0 |
| Withdrew: Protocol violation | 0 | 8 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 17 | 0 |
| Withdrew: Lost to follow-up | 0 | 11 | 0 |
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.
| score on a scale | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo |
|---|---|---|---|
| Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | -18.9 ± 1.11 | -20.7 ± 1.16 | -19.7 ± 1.11 |
| days | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo |
|---|---|---|---|
| Time to First Sustained Response in Reduction of MADRS Total Score | 43 (36 to NA) | 38 (36 to NA) | 37 (30 to NA) |
The MADRS total score from baseline to Day 175 for patients that rolled over into the extension portion of the study (Part B)
| units on a scale | Lumateperone 42 mg (ITI-007 60 mg Tosylate) |
|---|---|
| Change From Baseline to Day 175 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | -8.9 ± 10.76 |
Incidence of Treatment-Emergent Adverse Events from baseline to Day 175 for patients that rolled over into the extension portion of the study (Part B)
| Participants | Lumateperone 42 mg (ITI-007 60 mg Tosylate) |
|---|---|
| Headache | 26 |
| Dry Mouth | 15 |
| Dizziness | 13 |
| Nausea | 13 |
| Somnolence | 11 |
| Anxiety | 10 |
| Irritability | 8 |
Collected over From signing ICF until end of study procedures (~10 weeks), including 6 weeks of double-blind treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Lumateperone 28 mg (ITI-007 40 mg Tosylate) | 0/180 (0%) | 5/180 (2.8%) | 72/180 (40%) |
| Part A Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 0/184 (0%) | 0/184 (0%) | 67/184 (36.4%) |
| Part A Placebo | 1/185 (0.5%) | 1/185 (0.5%) | 31/185 (16.8%) |
| Part B Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 0/127 (0%) | 4/127 (3.1%) | 55/127 (43.3%) |
| Event | Part A Lumateperone 28 mg (ITI-007 40 mg Tosylate) | Part A Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Part A Placebo | Part B Lumateperone 42 mg (ITI-007 60 mg Tosylate) |
|---|---|---|---|---|
| DepressionPsychiatric disorders | 1/180 | 0/184 | 0/185 | 1/127 |
| Suicidal IdeationPsychiatric disorders | 1/180 | 0/184 | 0/185 | 1/127 |
| Mental status changesPsychiatric disorders | 0/180 | 0/184 | 0/185 | 1/127 |
| colitis ulcerativeGastrointestinal disorders | 0/180 | 0/184 | 0/185 | 1/127 |
| ManiaPsychiatric disorders | 1/180 | 0/184 | 0/185 | 0/127 |
| Panic AttackPsychiatric disorders | 1/180 | 0/184 | 0/185 | 0/127 |
| Anemia postoperativeInjury, poisoning and procedural complications | 1/180 | 0/184 | 0/185 | 0/127 |
| Procedural hemorrhageInjury, poisoning and procedural complications | 1/180 | 0/184 | 0/185 | 0/127 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/180 | 0/184 | 0/185 | 0/127 |
| AgressionPsychiatric disorders | 0/180 | 0/184 | 1/185 | 0/127 |
| Event | Part A Lumateperone 28 mg (ITI-007 40 mg Tosylate) | Part A Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Part A Placebo | Part B Lumateperone 42 mg (ITI-007 60 mg Tosylate) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 35/180 | 20/184 | 10/185 | 26/127 |
| SomnolenceNervous system disorders | 21/180 | 24/184 | 7/185 | 11/127 |
| Dry MouthGastrointestinal disorders | 13/180 | 15/184 | 3/185 | 15/127 |
| NauseaGastrointestinal disorders | 12/180 | 16/184 | 7/185 | 13/127 |
| DizzinessNervous system disorders | 10/180 | 15/184 | 4/185 | 13/127 |
| AnxietyPsychiatric disorders | 1/180 | 2/184 | 3/185 | 10/127 |
| IrritabilityPsychiatric disorders | 3/180 | 3/184 | 1/185 | 8/127 |
| FatigueGeneral disorders | 11/180 | 4/184 | 3/185 | 4/127 |
| DiarrhoeaGastrointestinal disorders | 9/180 | 10/184 | 5/185 | 4/127 |
| VomitingGastrointestinal disorders | 5/180 | 10/184 | 0/185 | 6/127 |
All patients in Part A Safety Analysis set which contains all patients who received at least one dose of study medication.
| Age, Continuous(years) | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo | Total |
|---|---|---|---|---|
| Mean | 40.5 ± 12.12 | 42.7 ± 11.85 | 42.3 ± 13.13 | 41.9 ± 12.40 |
| Sex: Female, Male(Participants) | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo | Total |
|---|---|---|---|---|
| Female | 109 | 111 | 114 | 334 |
| Male | 71 | 73 | 71 | 215 |
| Race/Ethnicity, Customized(participants) | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo | Total |
|---|---|---|---|---|
| White | 100 | 106 | 98 | 304 |
| Black or African American | 75 | 72 | 80 | 227 |
| Asian | 1 | 2 | 3 | 6 |
| American Indian or Alaska Native | 0 | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 | 2 |
| Multiple | 4 | 1 | 1 | 6 |
| Not Reported | 0 | 0 | 1 | 1 |
| Montgomery Asberg Depression Rating Scale (MADRS)(units on a scale) | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | Placebo | Total |
|---|---|---|---|---|
| Mean | 35.8 ± 6.08 | 35.9 ± 5.79 | 34.7 ± 5.84 | 35.4 ± 5.92 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in Jan 2019, 37 months.
Results were first posted in Nov 2025, 6 years 9 months after primary completion. A results delay was requested in Jan 2020.
Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 37 months is above that.
Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumateperone
Intra-Cellular Therapies, Inc. →